
Are you interested in economic and financial news?
Bank Bonhôte is pleased to welcome you and puts at your disposal its finance experts.
–
USD/CHF | EUR/CHF | SMI | EURO STOXX 50 | DAX 30 | CAC 40 | FTSE 100 | S&P 500 | NASDAQ | NIKKEI | MSCI Emerging Markets | |
---|---|---|---|---|---|---|---|---|---|---|---|
Latest | 0.81 | 0.94 | 11'866.85 | 5'347.74 | 24'162.86 | 7'743.00 | 9'095.73 | 6'389.45 | 21'450.02 | 41'820.48 | 1'253.79 |
Trend | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | 3 |
YTD | -10.92% | 0.14% | 2.29% | 9.23% | 21.38% | 4.91% | 11.29% | 8.63% | 11.08% | 4.83% | 16.58% |
(values from the Friday preceding publication)
–
The US unveiled its latest set of trade deals on 1 August, to take effect on 7 August. But Switzerland was unilaterally slapped with a 39% flat rate on its exports despite last-minute efforts to avoid being hit with such an exorbitant rate (which places Switzerland in the top four worst-off countries). The impact is hard to determine as precise details are lacking, such as how pharmaceuticals – Switzerland’s largest export to the US – will be treated. Straight away the Swiss GDP forecast was cut to 0.9% from 1.1%. But it is worth noting that while the US is Switzerland’s second export market, accounting for 13% in 2024, exports in reality subject to tariffs represent only a rough 10% of the total. Moreover, most SMI companies are out of scope, as much of the production for the US market takes place locally. In a nutshell, precision engineering, watchmaking, medtech and food & beverage are those sectors hit the hardest.
Focusing on individual sectors, the White House has unveiled a 100% additional levy on semiconductors made outside the US. The pharmaceutical industry is also facing more threats, including possibly a 250% additional levy on medication imports, unless price cuts can be implemented before September. Last but not least, a new duty on 1-kg and 100-ounce gold bars originating from Switzerland could upend gold prices, compounding their exposure to trade policy changes.
–
Recent US statistics have shown business slowing more quickly than expected. Unemployment is up, while the ISM manufacturing index has plunged to its lowest level since October 2024. Its services counterpart also contracted unexpectedly. These data have added to the case for a Fed rate cut in September, even though the rate-setting committee seems divided on the subject.
Meanwhile, the resignation of an FOMC member has opened the door to Stephen Miran, who is close to President Trump. His appointment still requires Senate confirmation. If approved, it could stoke tensions within the Fed, especially from the dissidents calling for a looser monetary policy.
Europe has been a mix of good and bad. PMIs in July pointed to marginally lower economic activity, with the Eurozone composite index dropping below the 51 mark. But Germany saw a small improvement as its index rose to 50.6, although manufacturing remains vulnerable. Global trade tensions are dampening growth, exports and investor confidence in Europe.
Against this backdrop equity indices have moved cautiously ahead. The S&P 500 ended the week up by 2.43%, Nasdaq by 3.73%, the Stoxx Europe 600 by 2.11% while the SMI edged up 0.26%.
This document is provided for your information only. It has been compiledfrom information collected from sources believed to be reliable and up to date, with no warranty as to its accuracy or completeness.By their very nature, markets and financial products are subject to the risk of substantial losses which may be incompatible with your risk tolerance.Any past performance that may be reflected in this documentis not a reliable indicator of future results.Nothing contained in this document should be construed as professional or investment advice. This document is not an offer to you to sell or a solicitation of an offer to buy any securities or any other financial product of any nature, and the Bank assumes no liability whatsoever in respect of this document.The Bank reserves the right, where necessary, to depart from the opinions expressed in this document, particularly in connection with the management of its clients’ mandates and the management of certain collective investments.The Bank is a Swiss bank subject to regulation and supervision by the Swiss Financial Market Supervisory Authority (FINMA).It is not authorised or supervised by any foreign regulator.Consequently, the publication of this document outside Switzerland, and the sale of certain products to investors resident or domiciled outside Switzerland may be subject to restrictions or prohibitions under foreign law.It is your responsibility to seek information regarding your status in this respect and to comply with all applicable laws and regulations.We strongly advise you to seek independentlegal and financial advice from qualified professional advisers before taking any decision based on the contents of this publication.